These stocks are definitely keepers.
It is hard to productionalize data science use cases, especially because the journey from experimentation is lacking standardisation. Thus, this project aims at boosting, scalability, productivity and ...
Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...
Vertex, Inc. (NASDAQ:VERX) reported weaker-than-expected sales for the second quarter and cut its FY25 sales guidance below estimates on Wednesday. Vertex reported quarterly earnings of 15 cents per ...
After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into ...
Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...
Vertex Pharmaceuticals Incorporated VRTX stock has declined 8.9% in the past three months. The deterioration was due to soft first-quarter results, slower-than-expected uptake of its newer drugs as ...
Vertex Pharmaceuticals' shares dropped due to poor first-quarter results. The company tends to run up after significant price drops. Vertex's business and prospects remain attractive. However, ...
Vertex is a brand with a storied past. It was one of the watchmakers that provided watches to the British Ministry of Defence (MoD) during World War II. The watch we are looking at today, the Vertex ...
May 5 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab missed Wall Street estimates for quarterly results on Monday due to lower-than-expected sales of its cystic fibrosis (CF) drug Trikafta ...
- VX-264 Phase 1/2 enrollment and dosing complete in Parts A and B: VX-264 was generally safe and well tolerated; efficacy data are not supportive of further clinical advancement - - Zimislecel ...